Menu
← Oncology Approval Tracker
FDA DECISION ·
Truseltiq
infigratinib · QED Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement by an FDA-approved test. FDA withdrew approval on May 16, 2024.
LAMPGEN ANALYSIS
Why it matters
The accelerated action addressed previously treated FGFR2-altered biliary cancer and was later withdrawn.
What research teams should watch
Retain the FGFR2 alteration class, prior therapy and both regulatory dates for historical comparisons.
PRIMARY RECORDS